Further reinforcing this connection, the emergence of “amyloid beta peptide” as a burst keyword in reviews not only confirms the relevance of Alzheimer’s disease to epilepsy research but also underscores a broader conceptual integration—where synaptic dysfunction, amyloid pathology, and seizure susceptibility are viewed as interrelated processes. The gene discussed is APP; the disease is amyloidosis.